pimonidazole has been researched along with Lymphoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kashino, G; Kinashi, Y; Liu, Y; Masunaga, S; Nagasawa, H; Ono, K; Sakurai, Y; Suzuki, M; Tanaka, H | 1 |
| Kondo, N; Maruhashi, A; Masunaga, S; Narabayashi, M; Ono, K; Sakurai, Y; Suzuki, M; Tanaka, H | 1 |
| Hirayama, R; Kondo, N; Maruhashi, A; Masunaga, S; Matsumoto, Y; Narabayashi, M; Ono, K; Sakurai, Y; Suzuki, M; Tanaka, H; Uzawa, A | 1 |
3 other study(ies) available for pimonidazole and Lymphoma
| Article | Year |
|---|---|
Evaluation of the radiosensitivity of the oxygenated tumor cell fractions in quiescent cell populations within solid tumors.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Radiation; Female; Gamma Rays; Lymphoma; Mice; Mice, Inbred C57BL; Micronucleus Tests; Nitroimidazoles; Oxygen; Radiation Tolerance | 2010 |
Wortmannin efficiently suppresses the recovery from radiation-induced damage in pimonidazole-unlabeled quiescent tumor cell population.
Topics: Androstadienes; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; DNA Damage; Drug Interactions; Drug Synergism; Lymphoma; Mice; Mice, Inbred C57BL; Nitroimidazoles; Radiation-Sensitizing Agents; Staining and Labeling; Treatment Outcome; Wortmannin | 2013 |
Radiosensitivity of pimonidazole-unlabelled intratumour quiescent cell population to γ-rays, accelerated carbon ion beams and boron neutron capture reaction.
Topics: Animals; Boron Neutron Capture Therapy; Carbon; Cell Line, Tumor; Gamma Rays; Heavy Ion Radiotherapy; Lymphoma; Mice; Mice, Inbred C57BL; Nitroimidazoles; Radiation Tolerance; Radiation-Sensitizing Agents; Radiotherapy, High-Energy; Treatment Outcome | 2013 |